3647 results for «545»
3647 results
The Navitor with FlexNav TAVI system: when smooth implantability allows to optimise TAVI outcomes
21 Nov 2021 – From PCR London Valves 2021
In this session from the PCR London Valves 2021 Congress, find out more about the new Navitor valve and FlexNav delivery system, discover how to achieve favourable patient outcomes, and learn how choosing a device can impact patient lifetime management.
...Not just TAVI
21 Nov 2021 – From PCR London Valves 2021
Browse this page to discover simultaneous TAVR and tricuspid valve-in-valve, combined percutaneous valve-in-valve TAVI and mitral repair in degenerated freestyle full root, paravalvular leak post TAVR causing hemolysis treated with balloon dilatation and PVL closure, and much more!
Best cases session
21 Nov 2021 – From PCR London Valves 2021
This session from the PCR London Valves 2021 Congress compiles a series of the best cases submitted during this edition. Discover, among others, cases of severe aortic valve and ostial coronary disease, as well as transcatheter valvular lithotripsy in cases with severely calcific aortic or mitral...
Best cases and research unveiled at AICT-Asia PCR 2021
08 Oct 2021 – From AICT-AsiaPCR 2021
Watch this session to discover some of the best cases and research unveiled at AICT-Asia PCR 2021: positive remodelling of coronary arteries on CT coronary angiogram, investigation of heavy metals in coronary artery tissues in autopsy cases, DEB vs. DES in the main vessel for treatment of...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
PANTHER - P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease
30 Aug 2022
Elad Asher provides his take on the PANTHER trial which was presented at the ESC Congress 2022 in Barcelona
Author
Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)
08 Apr 2024
Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.
Author
